I
n an open randomized trial of Malawian infants <60 days of age with possible severe bacterial infection (pSBI), we compared parenteral benzylpenicillin plus gentamicin with ceftriaxone as firstline treatment, assessing outcome and adverse events.
BACKGROUND
Clinically suspected pSBIs are common in low-income settings, especially in the first month of life when mortality and morbidity are high. 1 Early and appropriate therapy is critical to a good outcome. Antimicrobial therapy is guided by World Health Organization (WHO) recommendations: first-line therapy with parenteral benzylpenicillin and gentamicin and second-line treatment with cefotaxime or ceftriaxone. 2 Gentamicin has a potential for toxicity, especially hearing loss, but methods of monitoring blood concentrations of the drug are rarely available. There are no studies comparing the 2 regimens for efficacy, adverse events and outcome. pSBI includes severe pneumonia, sepsis and meningitis. The WHO Young Infants Sepsis Study Group reported that in a multicenter study in low-income countries in Asia and Africa, the 3 most common causes of pSBI found were Gram-negative enteric bacteria, group B Streptococcus (GBS) and Streptococcus pneumoniae. 3 In a meta-analysis of reports from 13 low-income settings, Staphylococcus aureus, Klebsiella spp. and Escherichia coli accounted for 55% (39%-70%) of culture-positive sepsis in all infants; 4 findings confirmed in a review of 21 studies, published after 2000, of neonatal invasive bacteremia in low-income settings, 10 of which were in sub-Saharan settings. 5 In a 6-country review of bacterial meningitis, resistance to second and third generation cephalosporins was present in >50% of all isolates, and 44% of Gram-negative isolates were gentamicin resistant. 6 Early-onset sepsis (<7 days) is often associated with risk factors in the mother and/or delivery, and the causative agents are GBS, S. aureus and Gram-negative bacteria such as E. coli. Lateonset infections (7-60 days) are commonly caused by bacteria such as S. pneumoniae, S. aureus, Klebsiella pneumoniae and also GBS. 2 In high-income settings, first-line antimicrobial treatment is usually benzylpenicillin or ampicillin and gentamicin for nonmeningitis cases, and second-line antimicrobial therapy is cefotaxime with ampicillin for meningitis cases. The ampicillin is to cover Listeria monocytogenes infections. 7 Ceftriaxone has been avoided in infants because of perceived safety issues, especially in infants who are jaundiced or hypoalbuminemic, 8 because ceftriaxone can cause biliary sludging, although this is reversed when treatment ceases and has no persisting sequelae. [8] [9] [10] [11] Ceftriaxone can form ceftriaxone-calcium complexes if given within 48 hours of a calcium-containing intravenous (IV) infusion. These complexes precipitate in IV fluid lines, the lungs and the kidneys, sometimes with fatal results. [12] [13] [14] Some national guidelines advise against using ceftriaxone in premature babies until they attain the gestational age of 41 weeks. 15 Ceftriaxone is still the drug of choice in neonatal gonorrheal ophthalmitis.
exceptionally rare. This may be because a typical Malawian diet does not include unpasteurized dairy products or salads. Surrounding countries such as Kenya, South Africa and Zimbabwe report similar causes of pSBI as Malawi. [18] [19] [20] Cephalosporins are bactericidal antibiotics, and although central nervous system penetration is modest, higher doses safely achieve therapeutic CSF drug levels. In Malawi, benzylpenicillin is appropriate for GBS infections and for most S. pneumoniae infections. 21, 22 K. pneumoniae and many other Gram-negative bacteria are increasingly resistant to gentamicin. 4, 23 The recommended WHO first-line therapy may be an inadequate empirical therapy where Gram-negative bacteria account for half or more of all cases of SBI in infants <2 months of age. For this reason, we compared benzylpenicillin and gentamicin with ceftriaxone as first-line treatment for pSBI in infants and monitored for safety, especially jaundice, during therapy.
MATERIALS AND METHODS
This was an open randomized trial carried out in the pediatric department of the Queen Elizabeth Central Hospital in Blantyre, Malawi, from March 2010 to February 2013. Queen Elizabeth Central Hospital is a 1100-bedded public government hospital; it is also the main teaching hospital of the Malawi medical school. It serves as the referral hospital for the southern half of the country and also as the district hospital for Blantyre. The children's department admits 28,000 children a year, and about 80,000 children are seen annually in the emergency unit.
Inclusion Criteria
Children ≤2 months of age in whom there was clinical suspicion of severe sepsis, pneumonia or meningitis were eligible for inclusion. Following WHO guidelines, pSBI (including severe pneumonia, sepsis and Bacterial meningitis (BM)) was suspected in the presence of convulsions, bulging fontanelle, lethargy, coma, poor feeding, irritability, apneic episodes or abnormal cry. 24 In infants <7 days of age, an extended diagnostic algorithm included fever, agitation, no spontaneous movement, cyanosis, slow capillary refill (<3 seconds) and lower chest wall in-drawing.
Enrollment took place after the guardian was fully informed and written consent was given. We recorded demographic, clinical and laboratory findings, including details about the pregnancy and the delivery.
Exclusion Criteria
Infants not to be enrolled were as follows: those with clinical severe jaundice (yellow discoloration of the skin extending to the lower limbs), those with known hypersensitivity to any of the 3 antibiotics and those who had been hospitalized for >72 hours, to avoid enrolling nosocomial infections. Children with previous neurologic abnormalities such as hydrocephalus and neural tube defects were not enrolled. Excluded patients received standard treatment of benzylpenicillin and gentamicin.
Endpoints
The primary endpoints were differences in outcome and occurrence of jaundice between the 2 treatment groups.
Randomization
Randomization was by computer-generated numbers in blocks of 10. Treatment allocations were sealed in consecutively numbered opaque envelopes and opened in numerical order by the recruiting clinician at enrollment. Allocation was either to benzylpenicillin 50,000 IU/kg 8 hourly IV (100,000 IU 8 hourly IV for BM) and daily gentamicin 6 mg/kg IV (standard smaller doses for low birth weight infants and very premature babies) or to ceftriaxone IV 50-100 mg/kg once daily (depending on age) for 5-14 days.
Samples on Admission
Laboratory investigations were carried out at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme Laboratories, which are externally quality controlled. A blood sample was taken for a full blood count, culture, electrolytes, glucose and an HIV antibody test (Determine DETERMINE HIV-1/2 TEST, ALERE FRANCE ). All infants testing positive by HIV antibody test had a blood sample tested by polymerase chain reaction to identify active HIV infection.
CSF was taken for biochemistry, microscopy and culture. A positive CSF was one in which a culture was positive or the white cell count was >50 cells/μL with neutrophils forming the greater proportion of the cells.
Clinical Monitoring And Care
All infants were monitored by study nurses every 2-4 hours and seen at least twice daily by the study team. Most infants had hearing tests and when clinically appropriate, an ultrasound scan of the head. Bilirubin levels were measured twice daily with a transcutaneous bilirubinometer (Konica Minolta Drager Air Shields JM 103 Drägerwerk AG & Co. Lübeck, Germany ). Magnetic resonance imagings were carried out when their findings might benefit the child.
We provided supportive care according to unit protocols. Calcium is not added to any infusions, and serum gentamicin levels are not available.
If the infant deteriorated despite the treatment given, and after discussion with the principal investigator, an appropriate antibiotic could be added to the treatment schedule or a switch made to the antibiotic(s) in the other study arm. If the CSF or blood culture report showed that a child was receiving inappropriate antimicrobial therapy for the bacteria grown, the treatment was changed for a more suitable antibiotic. 
Follow-up
Follow-up was at 1 and 6 months after hospital discharge when neurologic and hearing assessments were done. Age-appropriate hearing tests were carried out by trained nurses using oto-evoked potentials (Echocheck, Otodynamics Ltd Hatfield, UK ) and distraction tests. The neurologic assessment was made by a trained research clinician.
Sample Size
To detect a 40% lower case fatality rate in the ceftriaxone group than in the benzylpenicillin and gentamicin group (ie, to reduce the overall case fatality rate of meningitis from 50% to 30%) with a confidence of 90% and power of 80% required 107 infants in each arm (total: 214). To detect a difference in jaundice development in the ceftriaxone group of 18% compared with 8% in the penicillin and gentamicin group, the sample size needed with a confidence of 90% and power of 80% was 158 in each arm (total: 316). To allow for mortality (much of it early) and loss to followup, an extra 10% were to be recruited; that is, 174 to each group: 348 in total.
Statistical Analysis
Statistical analysis was, per protocol, done using Stata version 14.0 (StataCorp, College Station, TX). The difference in means of normally distributed variables was performed using an independent samples t test. χ 2 tests were used to assess relationship between categorical variables. Univariate logistic regression model was used to assess factors associated with poor outcome to obtain unadjusted odds ratios. Multivariate 
Adverse Events
Severe adverse events were reported to a data safety management board through the clinical monitor within 48 hours of their occurrence. The main safety endpoint for ceftriaxone was a transcutaneous bilirubin level at which phototherapy would be instituted. This level depended on gestational and postnatal age according to departmental bilirubin level graphs (Tables, Supplemental Digital Content 1 and 2, http://links.lww.com/INF/C692 and http://links.lww. com/INF/C693). If levels were reached that required phototherapy, it was commenced and 8 hourly transcutaneous bilirubin levels were measured. If bilirubin concentrations decreased or remained stable, further doses of ceftriaxone were given and monitoring continued. If bilirubin concentrations increased, no further ceftriaxone was given.
Serious events included deaths, jaundice levels at or beyond "phototherapy" levels, anemia (Hb: <6 g/dL) while on therapy and serious adverse drug reactions (rashes, bronchospasm and anaphylactic shock).
Any changes from one antibiotic to another were reported, and the reasons for change were documented. The study was to be stopped if bilirubin levels requiring a change in antibiotic therapy were found in 30% more of the children receiving ceftriaxone than of those receiving benzylpenicillin and gentamicin.
Ethical Considerations
Benzylpenicillin and gentamicin are widely used to treat neonatal infections despite the theoretical complications of renal failure and hearing loss. Ceftriaxone can cause conjugated bilirubinemia and jaundice without permanent sequelae. Ceftriaxone has been used for several years in many centers across the region as second-line treatment for neonatal infections. Nevertheless, because of these theoretical complications, all infants were monitored closely.
All guardians gave written consent to be enrolled after being fully informed of the study. Permission was granted by the College of Medicine Research and Ethics Committee to undertake the study (P2010/819), and the trial was registered with clinicaltrials. gov (NCT01247909).
RESULTS
From March 2010 to Feb 2013, a total of 351 infants less than 60 days of age were enrolled; 1 parent withdrew consent before signing, and 2 infants were deemed not to require antibiotics. The remaining 348 were included in analyses (Fig. 1 ). Of these, 161 
All diploccici, microcci and bacilli were considered contaminants. Coagulase-negative staphylococci and alpha-hemolytic streptococci may have been contaminants, but some of the infants from whom the samples were taken were very ill.
*Twelve CSFs with no growth on culture had white cell counts (number of cells = 23 -clumps in pus) suggestive of meningitis, 3 of these infants had positive blood cultures (1 each of GBS, coagulase-negative Staphylococcus and alpha-hemolytic Streptococcus, †1 had Gram-positive diplococci on Gram stain but was culture negative). ‡The Gram-negative bacteria were Escherichia coli 3, Acinetobacter baumannii 2, Salmonella typhimurium 1, Enterobacter cloacae 1 and Acinetobacter lwoffii 1. (46.5%) were given gentamicin/benzylpenicillin and 170 received ceftriaxone; 17 received both. Baseline characteristics were similar in the 2 groups, except for prevalence of clinical jaundice (n = 12; 6.5% in the penicillin v 23; 14% in the ceftriaxone group; P = 0.02) ( Table 1) . Overall inpatient mortality was 12% (n = 41), and a further 11 died within 6 months of discharge (total mortality: n = 52; 15%). Sequelae were found in 4.6% (n =16) at hospital discharge and a further 17 (total: 33; 12.6%) of 261 survivors at 6 months after discharge (Fig. 1) . Causes of death after discharge could not be verified, but 6 (18.7%) had neurologic sequelae after meningitis, 4 had significant congenital abnormalities, 2 HIV-positive infants had further admissions for probable Pneumocystis jirovecii pneumonia , 4 had been admitted with severe shock or sepsis and no cause for later death was given.
Of the 348 patients, 54 (15.5%) did not have a lumbar puncture done, 42 (14.3%) of the remaining 294 had positive CSF cultures of which 15 (36.6%) were GBS and 6 (14.6%) were Gramnegative bacteria such as Acinetobacter baumannii, E. coli and K. pneumoniae (Table 2) .
Blood cultures were done in 348 children; 105 (30.1%) were positive; of these, 62 (59%) grew coagulase-negative staphylococci, 9 (8.5%) were Gram-negative bacteria, 15 (14.3%) were GBS and 11 (10.5%) were S. aureus (Table 2) . Overall, more children with a positive than a negative CSF or blood culture had a poor outcome [25 (44%) vs. 67 (33%); P = 0.003 and 21 (41%) vs. 54 (30%); P = 0.04, respectively] (Table, Supplemental Digital Content 3, http://links.lww.com/INF/ C694). Coagulase-negative staphylococci and alpha-hemolytic streptococci may have been contaminants, but some of the infants from whom the samples were taken were very ill. Removing these bacteria from analyses made no difference to the findings. The combined outcome by CSF and blood culture results comparing no growth with growth (137 vs. 122) was also significant (P = 0.017) (Table, Supplemental Digital Content 3, http://links.lww.com/INF/C694).
Outcomes were similar between the 2 treatment groups; inpatient mortality was 11.2% in both the benzylpenicillin and gentamicin and the ceftriaxone arms (Table 2) . At 6 months postdischarge, deaths were 13.7% and 16.5% and sequelae in survivors were 14.5% and 11.2%, respectively (Fig. 1) .
On multivariate analysis, weight on admission, convulsions, not sucking, an oxygen saturation level <90% and positive blood culture were each associated significantly with mortality and sequelae (Table 3) .
More infants in the penicillin/gentamicin group were clinically jaundiced on admission and more eventually required phototherapy: n = 19; 15% versus 7; 5%, P = 0.03 (Table 4) . Fifteen infants received phototherapy for 1-2 days, 8 for 3-4 days, 6 for 5-6 days and 4 for 7-11 days. Of the infants receiving >5 days of phototherapy, 2 were on ceftriaxone and 6 were on benzylpenicillin; 1 received both drug treatments.
Thirteen (6%) of 216 children who were tested had bilateral hearing loss; 8 (61.5%) also had neurologic sequelae suggesting that the cause was the underlying infection. In 4 of the 13 infants with bilateral hearing loss, a lumbar puncture was not done as the infants were too sick; 8 of the remaining 9 infants had a positive culture of blood or CSF. There was no significant difference between the treatment groups (Table 5) . 
